The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.
Michele Maio
Consultant or Advisory Role - Bristol-Myers Squibb
Alessandro Testori
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Amgen
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Ruggero Ridolfi
No relevant relationships to disclose
Mario Santinami
No relevant relationships to disclose
Lorenzo Pilla
No relevant relationships to disclose
Paola Queirolo
Consultant or Advisory Role - GlaxoSmithKline; Roche
Marco Grosso
No relevant relationships to disclose
Ester Simeone
No relevant relationships to disclose
Stefania Vittoria, Luisa Nicoletti
No relevant relationships to disclose
Licia Rivoltini
No relevant relationships to disclose
Pier Francesco Ferrucci
No relevant relationships to disclose
Giorgio Parmiani
Research Funding - NIBIT(ItaianNetwork ForTumor Biotherapy)
Anna Maria Di Giacomo
No relevant relationships to disclose